iCell in the News

  • iCell Presents Positive New Follow-up Clinical Data Confirming BCMA CD19 cCAR Safely Delivers Long-term Medication Free Complete Remission from Systemic Lupus Erythematosus & Lupus Nephritis at EULAR 2024 [June 2024] Read More

  • iCell Gene Therapeutics Announces Positive Clinical Data from Investigator Initiated Phase 1 Trial Evaluating BCMA-CD19 Compound CAR in Patients with Systemic Lupus Erythematosus/Lupus Nephritis Published in Annals of the Rheumatic Diseases [May 2024] Read More

  • iCell Gene Therapeutics Announces cCAR-T Clinical Publication in Stem Cell Reviews and Reports Journal. (September 2021)  Read more​

  • Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells, published by Stem Cell Reports, January 2021) Read more

  • FDA awards grant to fund new clinical trials to advance the development of iCell Gene Therapeutic's CD4CAR T cell therapy for the treatment of rare disease (October 2020) Read more

  • iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at 61st American Society of Hematology Annual Meeting​. (Nov. 14, 2019) Read more

  • Targeting Relapse with CD19-CD123 Compound CAR Therapy. Yan, et al., accepted for publication, Nov. 2019. In press​

  • First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: ASH (Nov 4, 2018):  Update on Phase 1 Clinical Trial Read More

  • Presidential symposium of the European Hematology Association Congress   (Jun 14, 2018)​:  Report for the CLL1-CD33 cCAR here  and a panel discussion here​​​

  • A compound chimeric antigen receptor strategy for targeting multiple myeloma published in Leukemia. (Sep 27, 2017) Read more​​​ 

  • ​​iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at 61st American Society of Hematology Annual Meeting​. (Nov. 14, 2019) Read more

  • Characterization of an anti-CD5 directed CAR T-cell against T-cell malignancies, accepted for publication, Stem Cell Reviews and Reports, Nov. 2019.​Stony Brook University, iCell Gene Therapeutics and University of Louisville collaborate on first in human clinical trial of CAR-T cells targeting CD4 protein for aggressive T-cell leukemia and lymphoma (Oct 7, 2018) Read more

  • iCell Gene Therapeutics receives Orphan Drug Designation for CD5CAR for treatment of T cell leukemia and lymphomas that are positive for CD5. (Oct 16, 2017)​​

  • iCell Gene Therapeutics receives Orphan Drug Designation for CAR-T targeting peripheral T-cell lymphoma (PTCL) (Aug 11, 2016) Read more​​​​

  • CD4CAR T cell paper published in Leukemia  (Nov 9, 2015) Read more

  • CD5CAR NK cell paper published in Leukemia (Feb 12, 2017) Read more​​​

  • Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells. Pinz KG, et al., Oncotarget. 2017 www.ncbi.nlm.nih.gov/pubmed/29348865 Read more

  • CD3CAR NK cell paper published in Oncotarget (Aug 31, 2016) Read more​
    iCell Gene Therapeutics and Applied DNA Sciences collaborate on non-viral plasmid-free manufacturing platform, October 2018.